Free tool
FAERS Monitor: Xyzal
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022064 or its brand name (Xyzal, Levocetirizine Dihydrochloride). Reports on generic versions are filed under their own applications.
Reports
18,341
Serious
9,290
51% of reports
Hospitalization
3,893
Death reported
966
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,535
- fatigue1,340
- headache1,232
- pruritus1,204
- nausea1,069
- dyspnoea1,055
- diarrhoea990
- somnolence926
- dizziness823
- arthralgia781
- cough764
- rash758
- pyrexia715
- pain712
- off label use709
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 10 |
| 2006 | 6 |
| 2007 | 25 |
| 2008 | 161 |
| 2009 | 238 |
| 2010 | 262 |
| 2011 | 438 |
| 2012 | 576 |
| 2013 | 396 |
| 2014 | 387 |
| 2015 | 554 |
| 2016 | 828 |
| 2017 | 814 |
| 2018 | 977 |
| 2019 | 1,693 |
| 2020 | 1,545 |
| 2021 | 1,240 |
| 2022 | 1,544 |
| 2023 | 1,669 |
| 2024 | 1,797 |
| 2025 | 1,800 |
| 2026 | 1,376 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,818 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| somnolenceSignal | 926 | 5.3 | 5.0 | 3,237 |
| pruritusSignal | 1,204 | 3.6 | 3.4 | 2,294 |
| coughSignal | 764 | 3.1 | 2.9 | 1,117 |
| pyrexiaSignal | 715 | 2.4 | 2.2 | 575 |
| headacheSignal | 1,232 | 2.3 | 2.1 | 885 |
| arthralgiaSignal | 781 | 2.2 | 2.0 | 492 |
| dyspnoeaSignal | 1,055 | 2.1 | 2.0 | 655 |
| rash | 758 | 2.0 | 1.9 | 383 |
| fatigue | 1,340 | 2.0 | 1.9 | 668 |
| dizziness | 823 | 1.9 | 1.8 | 354 |
| diarrhoea | 990 | 1.8 | 1.7 | 334 |
| nausea | 1,069 | 1.5 | 1.5 | 216 |
| drug ineffective | 1,535 | 1.3 | 1.3 | 138 |
| pain | 712 | 1.3 | 1.2 | 60 |
| off label use | 709 | 0.9 | 0.9 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.